News
OncoBeta® receives Corporate Excellence Award 2019
OncoBeta recognized as the Most Compassionate Skin Cancer Therapy Provider in 2019.
OncoBeta®, a Medical Device Company specialized in innovative…
First non-melanoma skin cancer patients treated with the Rhenium-SCT® in Germany
The first Rhenium-SCT® treatment was accomplished by the interregional professional association for nuclear medicine in Hanau
Dr. Lutz-Hendrik…
OncoBeta® chosen as a 2019 Red Herring Top 100 Europe Winner
OncoBeta® GmbH, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs),…
OncoBeta® GmbH is listed as one of the Top 20 MedTech Outlook Solution Providers in Europe
OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers…
First Non-Melanocytic Skin Cancer Patients treated with Rhenium-SCT in South Africa
University of Pretoria Prof. Mike Sathekge is First in South Africa to Treat Non-Melanocytic Skin Cancer Patients with Rhenium-SCT®
OncoBeta® GmbH,…
OncoBeta’s Rhenium-SCT® for Non-Melanoma Skin Cancer to start in South Africa
TAUTOMER / NATIVA the official Rhenium-SCT® (Skin Cancer Therapy) Distributor for Continental Africa
OncoBeta GmbH®, a commercial stage Medical…
OncoBeta GmbH® Announces Certification of its New Production Facility Partner MAP Medical Technologies Oy, Tikkakoski FINLAND
OncoBeta GmbH has today announced the certification of its new production facility partner MAP Medical Technologies Oy, Tikkakoski FINLAND, aiming to…
Rhenium-SCT® (Skin Cancer Therapy) now being offered in Bologna, Italy
OncoBeta® GmbH is privileged to announce the start of the next Rhenium-SCT® treatment center located in Bologna Italy.